Chimeric Therapeutics believes that novel cell therapies hold the potential to cure cancer. The ASX-listed company is at the cutting edge of discovering new cancer treatments, backed by its industry leading partners and a team of cell therapy pioneers and experts. Chimeric Therapeutics (ASX:CHM) is committed to developing the most innovative and promising cell therapies. The company has a pipeline of natural killer (NK) cell-derived therapies and T-cell-derived therapies under different phases of clinical trials. Ms. Jennifer Chow serves as the Chief Executive Officer and Managing Director of Chimeric Therapeutics. She has more than 20 years of experience in commercial strategy and marketing focused on cell therapy, hematology, and oncology. To get more updates about Australia, NZ, UK, Canada and US stock market news, investors education & insights, subscribe our channel at https://bit.ly/3cHKioy